The global market for Sustained and Controlled Release Formulations was valued at US$ million in the year 2024 and is projected to reach a revised size of US$ million by 2031, growing at a CAGR of %during the forecast period.
North American market for Sustained and Controlled Release Formulations is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Asia-Pacific market for Sustained and Controlled Release Formulations is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The major global manufacturers of Sustained and Controlled Release Formulations include Humanwell Healthcare Co.,Ltd., Nanjing Yiheng Pharmaceutical Co., Ltd., Jiangsu Hengrui Pharmaceuticals Co.,ltd., Qilu Pharmaceutical Co Ltd, Shanghai Pharmaceuticals Holding Co.,Ltd., Yangtze River Pharmaceutical (Group) Co., Ltd., PKU HealthCare Corp.,Ltd., Overseas Pharmaceuticals, Ltd., Novast Laboratories (China), LTD., Catalent, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Sustained and Controlled Release Formulations, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Sustained and Controlled Release Formulations.
The Sustained and Controlled Release Formulations market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Sustained and Controlled Release Formulations market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Sustained and Controlled Release Formulations manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
By Company
Humanwell Healthcare Co.,Ltd.
Nanjing Yiheng Pharmaceutical Co., Ltd.
Jiangsu Hengrui Pharmaceuticals Co.,ltd.
Qilu Pharmaceutical Co Ltd
Shanghai Pharmaceuticals Holding Co.,Ltd.
Yangtze River Pharmaceutical (Group) Co., Ltd.
PKU HealthCare Corp.,Ltd.
Overseas Pharmaceuticals, Ltd.
Novast Laboratories (China), LTD.
Catalent
AstraZeneca Plc
Oakwood Labs
Ascendia Pharma
Colorcon
Pfizer Inc.
Mylan
Sandoz
Segment by Type
Generic Drug
Original Drug
Segment by Application
Cardiovascular System Drugs
Nervous System Drugs
Digestive System and Metabolism
Other
Consumption by Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Europe
Germany
France
U.K.
Italy
Russia
Latin America
Mexico
Brazil
Argentina
Middle East and Africa
Turkey
Saudi Arabia
UAE
Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Sustained and Controlled Release Formulations manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Sustained and Controlled Release Formulations in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.鈥�
Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.
1 Sustained and Controlled Release Formulations 麻豆原创 Overview
1.1 Product Definition
1.2 Sustained and Controlled Release Formulations by Type
1.2.1 Global Sustained and Controlled Release Formulations 麻豆原创 Value Comparison by Type (2024 VS 2031)
1.2.2 Generic Drug
1.2.3 Original Drug
1.3 Sustained and Controlled Release Formulations by Application
1.3.1 Global Sustained and Controlled Release Formulations 麻豆原创 Value by Application (2024 VS 2031)
1.3.2 Cardiovascular System Drugs
1.3.3 Nervous System Drugs
1.3.4 Digestive System and Metabolism
1.3.5 Other
1.4 Global Sustained and Controlled Release Formulations 麻豆原创 Size Estimates and Forecasts
1.4.1 Global Sustained and Controlled Release Formulations Revenue 2020-2031
1.4.2 Global Sustained and Controlled Release Formulations Sales 2020-2031
1.4.3 Global Sustained and Controlled Release Formulations 麻豆原创 Average Price (2020-2031)
1.5 Assumptions and Limitations
2 Sustained and Controlled Release Formulations 麻豆原创 Competition by Manufacturers
2.1 Global Sustained and Controlled Release Formulations Sales 麻豆原创 Share by Manufacturers (2020-2025)
2.2 Global Sustained and Controlled Release Formulations Revenue 麻豆原创 Share by Manufacturers (2020-2025)
2.3 Global Sustained and Controlled Release Formulations Average Price by Manufacturers (2020-2025)
2.4 Global Key Players of Sustained and Controlled Release Formulations, Industry Ranking, 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Sustained and Controlled Release Formulations, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Sustained and Controlled Release Formulations, Product Type & Application
2.7 Global Key Manufacturers of Sustained and Controlled Release Formulations, Date of Enter into This Industry
2.8 Global Sustained and Controlled Release Formulations 麻豆原创 Competitive Situation and Trends
2.8.1 Global Sustained and Controlled Release Formulations 麻豆原创 Concentration Rate
2.8.2 The Global 5 and 10 Largest Sustained and Controlled Release Formulations Players 麻豆原创 Share by Revenue
2.8.3 Global Sustained and Controlled Release Formulations 麻豆原创 Share by Company Type (Tier 1, Tier 2, and Tier 3)
2.9 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Global Sustained and Controlled Release Formulations 麻豆原创 Scenario by Region
3.1 Global Sustained and Controlled Release Formulations 麻豆原创 Size by Region: 2020 Versus 2024 Versus 2031
3.2 Global Sustained and Controlled Release Formulations Sales by Region: 2020-2031
3.2.1 Global Sustained and Controlled Release Formulations Sales by Region: 2020-2025
3.2.2 Global Sustained and Controlled Release Formulations Sales by Region: 2026-2031
3.3 Global Sustained and Controlled Release Formulations Revenue by Region: 2020-2031
3.3.1 Global Sustained and Controlled Release Formulations Revenue by Region: 2020-2025
3.3.2 Global Sustained and Controlled Release Formulations Revenue by Region: 2026-2031
3.4 North America Sustained and Controlled Release Formulations 麻豆原创 Facts & Figures by Country
3.4.1 North America Sustained and Controlled Release Formulations 麻豆原创 Size by Country: 2020 VS 2024 VS 2031
3.4.2 North America Sustained and Controlled Release Formulations Sales by Country (2020-2031)
3.4.3 North America Sustained and Controlled Release Formulations Revenue by Country (2020-2031)
3.4.4 United States
3.4.5 Canada
3.5 Europe Sustained and Controlled Release Formulations 麻豆原创 Facts & Figures by Country
3.5.1 Europe Sustained and Controlled Release Formulations 麻豆原创 Size by Country: 2020 VS 2024 VS 2031
3.5.2 Europe Sustained and Controlled Release Formulations Sales by Country (2020-2031)
3.5.3 Europe Sustained and Controlled Release Formulations Revenue by Country (2020-2031)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Sustained and Controlled Release Formulations 麻豆原创 Facts & Figures by Region
3.6.1 Asia Pacific Sustained and Controlled Release Formulations 麻豆原创 Size by Region: 2020 VS 2024 VS 2031
3.6.2 Asia Pacific Sustained and Controlled Release Formulations Sales by Region (2020-2031)
3.6.3 Asia Pacific Sustained and Controlled Release Formulations Revenue by Region (2020-2031)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Southeast Asia
3.7 Latin America Sustained and Controlled Release Formulations 麻豆原创 Facts & Figures by Country
3.7.1 Latin America Sustained and Controlled Release Formulations 麻豆原创 Size by Country: 2020 VS 2024 VS 2031
3.7.2 Latin America Sustained and Controlled Release Formulations Sales by Country (2020-2031)
3.7.3 Latin America Sustained and Controlled Release Formulations Revenue by Country (2020-2031)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Sustained and Controlled Release Formulations 麻豆原创 Facts & Figures by Country
3.8.1 Middle East and Africa Sustained and Controlled Release Formulations 麻豆原创 Size by Country: 2020 VS 2024 VS 2031
3.8.2 Middle East and Africa Sustained and Controlled Release Formulations Sales by Country (2020-2031)
3.8.3 Middle East and Africa Sustained and Controlled Release Formulations Revenue by Country (2020-2031)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Sustained and Controlled Release Formulations Sales by Type (2020-2031)
4.1.1 Global Sustained and Controlled Release Formulations Sales by Type (2020-2025)
4.1.2 Global Sustained and Controlled Release Formulations Sales by Type (2026-2031)
4.1.3 Global Sustained and Controlled Release Formulations Sales 麻豆原创 Share by Type (2020-2031)
4.2 Global Sustained and Controlled Release Formulations Revenue by Type (2020-2031)
4.2.1 Global Sustained and Controlled Release Formulations Revenue by Type (2020-2025)
4.2.2 Global Sustained and Controlled Release Formulations Revenue by Type (2026-2031)
4.2.3 Global Sustained and Controlled Release Formulations Revenue 麻豆原创 Share by Type (2020-2031)
4.3 Global Sustained and Controlled Release Formulations Price by Type (2020-2031)
5 Segment by Application
5.1 Global Sustained and Controlled Release Formulations Sales by Application (2020-2031)
5.1.1 Global Sustained and Controlled Release Formulations Sales by Application (2020-2025)
5.1.2 Global Sustained and Controlled Release Formulations Sales by Application (2026-2031)
5.1.3 Global Sustained and Controlled Release Formulations Sales 麻豆原创 Share by Application (2020-2031)
5.2 Global Sustained and Controlled Release Formulations Revenue by Application (2020-2031)
5.2.1 Global Sustained and Controlled Release Formulations Revenue by Application (2020-2025)
5.2.2 Global Sustained and Controlled Release Formulations Revenue by Application (2026-2031)
5.2.3 Global Sustained and Controlled Release Formulations Revenue 麻豆原创 Share by Application (2020-2031)
5.3 Global Sustained and Controlled Release Formulations Price by Application (2020-2031)
6 Key Companies Profiled
6.1 Humanwell Healthcare Co.,Ltd.
6.1.1 Humanwell Healthcare Co.,Ltd. Company Information
6.1.2 Humanwell Healthcare Co.,Ltd. Description and Business Overview
6.1.3 Humanwell Healthcare Co.,Ltd. Sustained and Controlled Release Formulations Sales, Revenue and Gross Margin (2020-2025)
6.1.4 Humanwell Healthcare Co.,Ltd. Sustained and Controlled Release Formulations Product Portfolio
6.1.5 Humanwell Healthcare Co.,Ltd. Recent Developments/Updates
6.2 Nanjing Yiheng Pharmaceutical Co., Ltd.
6.2.1 Nanjing Yiheng Pharmaceutical Co., Ltd. Company Information
6.2.2 Nanjing Yiheng Pharmaceutical Co., Ltd. Description and Business Overview
6.2.3 Nanjing Yiheng Pharmaceutical Co., Ltd. Sustained and Controlled Release Formulations Sales, Revenue and Gross Margin (2020-2025)
6.2.4 Nanjing Yiheng Pharmaceutical Co., Ltd. Sustained and Controlled Release Formulations Product Portfolio
6.2.5 Nanjing Yiheng Pharmaceutical Co., Ltd. Recent Developments/Updates
6.3 Jiangsu Hengrui Pharmaceuticals Co.,ltd.
6.3.1 Jiangsu Hengrui Pharmaceuticals Co.,ltd. Company Information
6.3.2 Jiangsu Hengrui Pharmaceuticals Co.,ltd. Description and Business Overview
6.3.3 Jiangsu Hengrui Pharmaceuticals Co.,ltd. Sustained and Controlled Release Formulations Sales, Revenue and Gross Margin (2020-2025)
6.3.4 Jiangsu Hengrui Pharmaceuticals Co.,ltd. Sustained and Controlled Release Formulations Product Portfolio
6.3.5 Jiangsu Hengrui Pharmaceuticals Co.,ltd. Recent Developments/Updates
6.4 Qilu Pharmaceutical Co Ltd
6.4.1 Qilu Pharmaceutical Co Ltd Company Information
6.4.2 Qilu Pharmaceutical Co Ltd Description and Business Overview
6.4.3 Qilu Pharmaceutical Co Ltd Sustained and Controlled Release Formulations Sales, Revenue and Gross Margin (2020-2025)
6.4.4 Qilu Pharmaceutical Co Ltd Sustained and Controlled Release Formulations Product Portfolio
6.4.5 Qilu Pharmaceutical Co Ltd Recent Developments/Updates
6.5 Shanghai Pharmaceuticals Holding Co.,Ltd.
6.5.1 Shanghai Pharmaceuticals Holding Co.,Ltd. Company Information
6.5.2 Shanghai Pharmaceuticals Holding Co.,Ltd. Description and Business Overview
6.5.3 Shanghai Pharmaceuticals Holding Co.,Ltd. Sustained and Controlled Release Formulations Sales, Revenue and Gross Margin (2020-2025)
6.5.4 Shanghai Pharmaceuticals Holding Co.,Ltd. Sustained and Controlled Release Formulations Product Portfolio
6.5.5 Shanghai Pharmaceuticals Holding Co.,Ltd. Recent Developments/Updates
6.6 Yangtze River Pharmaceutical (Group) Co., Ltd.
6.6.1 Yangtze River Pharmaceutical (Group) Co., Ltd. Company Information
6.6.2 Yangtze River Pharmaceutical (Group) Co., Ltd. Description and Business Overview
6.6.3 Yangtze River Pharmaceutical (Group) Co., Ltd. Sustained and Controlled Release Formulations Sales, Revenue and Gross Margin (2020-2025)
6.6.4 Yangtze River Pharmaceutical (Group) Co., Ltd. Sustained and Controlled Release Formulations Product Portfolio
6.6.5 Yangtze River Pharmaceutical (Group) Co., Ltd. Recent Developments/Updates
6.7 PKU HealthCare Corp.,Ltd.
6.7.1 PKU HealthCare Corp.,Ltd. Company Information
6.7.2 PKU HealthCare Corp.,Ltd. Description and Business Overview
6.7.3 PKU HealthCare Corp.,Ltd. Sustained and Controlled Release Formulations Sales, Revenue and Gross Margin (2020-2025)
6.7.4 PKU HealthCare Corp.,Ltd. Sustained and Controlled Release Formulations Product Portfolio
6.7.5 PKU HealthCare Corp.,Ltd. Recent Developments/Updates
6.8 Overseas Pharmaceuticals, Ltd.
6.8.1 Overseas Pharmaceuticals, Ltd. Company Information
6.8.2 Overseas Pharmaceuticals, Ltd. Description and Business Overview
6.8.3 Overseas Pharmaceuticals, Ltd. Sustained and Controlled Release Formulations Sales, Revenue and Gross Margin (2020-2025)
6.8.4 Overseas Pharmaceuticals, Ltd. Sustained and Controlled Release Formulations Product Portfolio
6.8.5 Overseas Pharmaceuticals, Ltd. Recent Developments/Updates
6.9 Novast Laboratories (China), LTD.
6.9.1 Novast Laboratories (China), LTD. Company Information
6.9.2 Novast Laboratories (China), LTD. Description and Business Overview
6.9.3 Novast Laboratories (China), LTD. Sustained and Controlled Release Formulations Sales, Revenue and Gross Margin (2020-2025)
6.9.4 Novast Laboratories (China), LTD. Sustained and Controlled Release Formulations Product Portfolio
6.9.5 Novast Laboratories (China), LTD. Recent Developments/Updates
6.10 Catalent
6.10.1 Catalent Company Information
6.10.2 Catalent Description and Business Overview
6.10.3 Catalent Sustained and Controlled Release Formulations Sales, Revenue and Gross Margin (2020-2025)
6.10.4 Catalent Sustained and Controlled Release Formulations Product Portfolio
6.10.5 Catalent Recent Developments/Updates
6.11 AstraZeneca Plc
6.11.1 AstraZeneca Plc Company Information
6.11.2 AstraZeneca Plc Description and Business Overview
6.11.3 AstraZeneca Plc Sustained and Controlled Release Formulations Sales, Revenue and Gross Margin (2020-2025)
6.11.4 AstraZeneca Plc Sustained and Controlled Release Formulations Product Portfolio
6.11.5 AstraZeneca Plc Recent Developments/Updates
6.12 Oakwood Labs
6.12.1 Oakwood Labs Company Information
6.12.2 Oakwood Labs Description and Business Overview
6.12.3 Oakwood Labs Sustained and Controlled Release Formulations Sales, Revenue and Gross Margin (2020-2025)
6.12.4 Oakwood Labs Sustained and Controlled Release Formulations Product Portfolio
6.12.5 Oakwood Labs Recent Developments/Updates
6.13 Ascendia Pharma
6.13.1 Ascendia Pharma Company Information
6.13.2 Ascendia Pharma Description and Business Overview
6.13.3 Ascendia Pharma Sustained and Controlled Release Formulations Sales, Revenue and Gross Margin (2020-2025)
6.13.4 Ascendia Pharma Sustained and Controlled Release Formulations Product Portfolio
6.13.5 Ascendia Pharma Recent Developments/Updates
6.14 Colorcon
6.14.1 Colorcon Company Information
6.14.2 Colorcon Description and Business Overview
6.14.3 Colorcon Sustained and Controlled Release Formulations Sales, Revenue and Gross Margin (2020-2025)
6.14.4 Colorcon Sustained and Controlled Release Formulations Product Portfolio
6.14.5 Colorcon Recent Developments/Updates
6.15 Pfizer Inc.
6.15.1 Pfizer Inc. Company Information
6.15.2 Pfizer Inc. Description and Business Overview
6.15.3 Pfizer Inc. Sustained and Controlled Release Formulations Sales, Revenue and Gross Margin (2020-2025)
6.15.4 Pfizer Inc. Sustained and Controlled Release Formulations Product Portfolio
6.15.5 Pfizer Inc. Recent Developments/Updates
6.16 Mylan
6.16.1 Mylan Company Information
6.16.2 Mylan Description and Business Overview
6.16.3 Mylan Sustained and Controlled Release Formulations Sales, Revenue and Gross Margin (2020-2025)
6.16.4 Mylan Sustained and Controlled Release Formulations Product Portfolio
6.16.5 Mylan Recent Developments/Updates
6.17 Sandoz
6.17.1 Sandoz Company Information
6.17.2 Sandoz Description and Business Overview
6.17.3 Sandoz Sustained and Controlled Release Formulations Sales, Revenue and Gross Margin (2020-2025)
6.17.4 Sandoz Sustained and Controlled Release Formulations Product Portfolio
6.17.5 Sandoz Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Sustained and Controlled Release Formulations Industry Chain Analysis
7.2 Sustained and Controlled Release Formulations Raw Material Supply Analysis
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Sustained and Controlled Release Formulations Production Mode & Process Analysis
7.4 Sustained and Controlled Release Formulations Sales and 麻豆原创ing
7.4.1 Sustained and Controlled Release Formulations Sales Channels
7.4.2 Sustained and Controlled Release Formulations Distributors
7.5 Sustained and Controlled Release Formulations Customer Analysis
8 Sustained and Controlled Release Formulations 麻豆原创 Dynamics
8.1 Sustained and Controlled Release Formulations Industry Trends
8.2 Sustained and Controlled Release Formulations 麻豆原创 Drivers
8.3 Sustained and Controlled Release Formulations 麻豆原创 Challenges
8.4 Sustained and Controlled Release Formulations 麻豆原创 Restraints
9 Research Findings and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 麻豆原创 Size Estimation
10.1.3 麻豆原创 Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
Humanwell Healthcare Co.,Ltd.
Nanjing Yiheng Pharmaceutical Co., Ltd.
Jiangsu Hengrui Pharmaceuticals Co.,ltd.
Qilu Pharmaceutical Co Ltd
Shanghai Pharmaceuticals Holding Co.,Ltd.
Yangtze River Pharmaceutical (Group) Co., Ltd.
PKU HealthCare Corp.,Ltd.
Overseas Pharmaceuticals, Ltd.
Novast Laboratories (China), LTD.
Catalent
AstraZeneca Plc
Oakwood Labs
Ascendia Pharma
Colorcon
Pfizer Inc.
Mylan
Sandoz
听
听
*If Applicable.